rtPA联合药物治疗急性缺血性卒中的应用  

Application of rtPA Combined with Other Drugs in the Treatment of Acute Ischemic Stroke

作　　者：覃辉[1] 梁明坤[1] 张永全[1] 陆晖[1] 谭文澜[1] 

机构地区：[1]广西中医药大学附属瑞康医院,广西南宁530011

出　　处：《大众科技》2018年第8期86-89,共4页Popular Science & Technology

摘　　要：急性缺血性卒中(AIS)已成为老年人主要的致残及死亡原因之一,具有起病急、病死率高、神经功能恢复缓慢的特征。而超早期重组织型纤溶酶原激活剂(rtPA)溶栓治疗已经成为AIS的一个标准治疗方法。但溶栓治疗容易出现一系列并发症,限制了其在临床治疗中的应用。文章就rt PA联合其他药物治疗AIS进行综述,为临床治疗AIS提供参考。Acute ischemic stroke(AIS)has become one of the main causes of disability and death in the elderly.It has the characteristics of acute onset,high mortality and slow recovery of nerve function.The ultra-early recombinant tissue plasminogen activator(rtPA)thrombolytic therapy has become a standard treatment for AIS.However,thrombolytic therapy is prone to a series of complications,which limits its application in clinical treatment.This article reviews the treatment of AIS with rtPA therapy in combination with other drugs,which provides a reference for the clinic treatment of AIS.

关 键 词：RTPA 溶栓 急性缺血性卒中 联合治疗 

分 类 号：R743.3[医药卫生—神经病学与精神病学]